| Literature DB >> 34557264 |
Mateusz Maciejczyk1, Cezary Pawlukianiec2, Małgorzata Żendzian-Piotrowska1, Jerzy Robert Ładny3, Anna Zalewska4.
Abstract
Insulin resistance (IR) is a condition of impaired tissue response to insulin. Although there are many methods to diagnose IR, new biomarkers are still being sought for early and noninvasive diagnosis of the disease. Of particular interest in laboratory diagnostics is saliva collected in a stress-free, noninvasive, and straightforward manner. The purpose of the study was to evaluate the diagnostic utility of salivary redox biomarkers in preclinical studies in an animal model. The study was conducted on 20 male Wistar rats divided into two equal groups: a standard diet and a high-fat diet (HFD). In all rats fed the HFD, IR was confirmed by an elevated homeostasis model assessment (HOMA-IR) index. We have shown that IR is responsible for the depletion of the enzymatic (↓superoxide dismutase) and nonenzymatic (↓ascorbic acid, ↓reduced glutathione (GSH)) antioxidant barrier at both the central (serum/plasma) and salivary gland (saliva) levels. In IR rats, we also demonstrated significantly higher concentrations of protein/lipid oxidation (↑protein carbonyls, ↑4-hydroxynoneal (4-HNE)), glycation (↑advanced glycation end products), and nitration (↑3-nitrotyrosine) products in both saliva and blood plasma. Salivary nonenzymatic antioxidants and oxidative stress products generally correlate with their blood levels, while GSH and 4-HNE have the highest correlation coefficient. Salivary GSH and 4-HNE correlate with body weight and BMI and indices of carbohydrate metabolism (glucose, insulin, HOMA-IR) and proinflammatory adipokines (leptin, resistin, TNF-α). These biomarkers differentiate IR from healthy controls with very high sensitivity (100%) and specificity (100%). The high diagnostic utility of salivary GSH and 4-HNE is also confirmed by multivariate regression analysis. Summarizing, saliva can be used to assess the systemic antioxidant status and the intensity of systemic oxidative stress. Salivary GSH and 4-HNE may be potential biomarkers of IR progression. There is a need for human clinical trials to evaluate the diagnostic utility of salivary redox biomarkers in IR conditions.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34557264 PMCID: PMC8455206 DOI: 10.1155/2021/3734252
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
General characteristics of the control and high-fat diet fed (HFD) rats.
| Parameter | Control group | HFD group |
|---|---|---|
| Body weight (g) | 388 ± 34.16 | 537 ± 36.52∗∗∗∗ |
| BMI (g/cm2) | 0.66 ± 0.024 | 0.90 ± 0.016∗∗∗∗ |
| Energy intake (g/rat/week) | 206.4 ± 22.06 | 248.6 ± 38.23∗∗ |
| Food intake (g/day) | 18.07 ± 1.93 | 11.05 ± 1.70∗∗∗∗ |
| Plasma glucose (mg/dL) | 90.94 ± 3.31 | 146.4 ± 12.54∗∗∗∗ |
| Plasma insulin (mU/mL) | 78.65 ± 7.55 | 172.30 ± 12.07∗∗∗∗ |
| HOMA-IR | 1.72 ± 0.18 | 16.20 ± 0.65∗∗∗∗ |
| Plasma leptin (mU/mL) | 26.84 ± 2.88 | 49.40 ± 6.24∗∗∗∗ |
| Plasma resistin (mU/mL) | 184 ± 19.12 | 394 ± 39.51∗∗∗∗ |
| Plasma TNF- | 1010 ± 115.2 | 3248 ± 588.5∗∗∗∗ |
Abbreviations: BMI: body mass index; HFD: high-fat diet; HOMA-IR: homeostatic model assessment of insulin resistance; TNF-α: tumor necrosis factor α; ∗∗p < 0.01 vs. control; ∗∗∗∗p < 0.0001 vs. control.
Figure 1The effect of a high-fat diet (HFD) on salivary and plasma enzymatic antioxidants in rats. Abbreviations: C: control group; HFD: high-fat-diet group; CAT: catalase; GPx: glutathione peroxidase; GR: glutathione reductase; Px: peroxidase; SOD: superoxide dismutase; ∗∗p < 0.01 vs. control; ∗∗∗∗p < 0.0001 vs. control; ns: no significance.
Figure 2The effect of a high-fat diet (HFD) on salivary and plasma nonenzymatic antioxidants in rats. Abbreviations: C: control group; HFD: high-fat-diet group; AA: ascorbic acid; GSH: reduced glutathione; UA: uric acid; ∗p < 0.05 vs. control; ∗∗p < 0.01 vs. control; ∗∗∗p < 0.001 vs. control; ∗∗∗∗p < 0.0001 vs. control; ns: no significance.
Figure 3The effect of a high-fat diet (HFD) on salivary and plasma oxidative/nitrosative damage in rats. Abbreviations: C: control group; HFD: high-fat-diet group; 3-NT: 3-nitrotyrosine; 4-HNE: 4-hydroxynonenal; AGE: advanced glycation end products; PC: protein carbonyls; ∗p < 0.05 vs. control; ∗∗p < 0.01 vs. control; ∗∗∗p < 0.001 vs. control; ∗∗∗∗p < 0.0001 vs. control; ns: no significance.
Figure 4Correlations between salivary and plasma redox and metabolic parameters in rats. Abbreviations: 3-NT: 3-nitrotyrosine; 4-HNE: 4-hydroxynonenal; AA: ascorbic acid; AGE: advanced glycation end products; BMI: body mass index; BW: body weight; CAT: catalase; GSH: reduced glutathione; GR: glutathione reductase; HOMA-IR: homeostatic model assessment for insulin resistance; PC: protein carbonyls; Px: peroxidase; SOD: superoxide dismutase; TNF-α: tumor necrosis factor α; UA: uric acid.
Multiple regression analysis of the analyzed redox biomarkers.
| Parameter | ||||||
|---|---|---|---|---|---|---|
| Estimate | 95% CI | Estimate | 95% CI | |||
| Salivary CAT | 0.03866 | -0.1186 to 0.1959 | 0.5793 | 0.7877 | -0.6970 to 2.272 | 0.2499 |
| Salivary Px | -4.2 | -23.23 to 14.83 | 0.6178 | 57.27 | -122.3 to 236.9 | 0.4754 |
| Salivary GR | 0.07613 | -1.587 to 1.740 | 0.9169 | 1.356 | -14.35 to 17.06 | 0.844 |
| Salivary SOD | 0.02902 | -0.02624 to 0.08427 | 0.2544 | -0.4925 | -1.014 to 0.02913 | 0.0607 |
| Salivary AA | -1.039 | -5.541 to 3.462 | 0.602 | 3.56 | -38.93 to 46.05 | 0.8486 |
| Salivary GSH | -0.2338 | -0.3665 to -0.1011 | 0.0042 | -1.44 | -2.693 to -0.1877 | 0.0298 |
| Salivary UA | 0.01866 | -0.1543 to 0.1916 | 0.806 | 1.175 | -0.4573 to 2.808 | 0.1325 |
| Salivary PC | 0.2107 | -0.1228 to 0.5443 | 0.1788 | -0.9228 | -4.071 to 2.226 | 0.5106 |
| Salivary 3-NT | -0.2589 | -1.162 to 0.6447 | 0.5198 | 4.142 | -4.387 to 12.67 | 0.2885 |
| Salivary AGE | -0.01719 | -0.2152 to 0.1808 | 0.8432 | -0.3393 | -2.209 to 1.530 | 0.6806 |
| Salivary 4-HNE | -0.9857 | -4.660 to 2.688 | 0.546 | 47.96 | 13.29 to 82.64 | 0.0137 |
Abbreviations: 3-NT: 3-nitrotyrosine; 4-HNE: 4-hydroxynonenal; AA: ascorbic acid; AGE: advanced glycation end products; BMI: body mass index; CAT: catalase; CI: confidence interval; GSH: reduced glutathione; GR: glutathione reductase; HOMA-IR: homeostatic model assessment for insulin resistance; PC: protein carbonyls; Px: peroxidase; SOD: superoxide dismutase; UA: uric acid.
ROC analysis of the analyzed redox biomarkers.
| Biomarker | Saliva | Serum/plasma | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC | 95% CI | Cut-off | Sensitivity % | 95% CI | Specificity % | 95% CI | AUC | 95% CI | Cut-off | Sensitivity % | 95% CI | Specificity % | 95% CI | |||
| CAT | 0.76 | 0.5360 to 0.9840 | 0.0494 | >0.5592 | 60 | 31.27% to 83.18% | 60 | 31.27% to 83.18% | 1 | 1.000 to 1.000 | 0.0002 | <1.244 | 100 | 72.25% to 100.0% | 100 | 72.25% to 100.0% |
| Px/GPx | 0.84 | 0.6581 to 1.000 | 0.0102 | <29.80 | 70 | 39.68% to 89.22% | 70 | 39.68% to 89.22% | 0.63 | 0.3657 to 0.8943 | 0.3258 | <35.10 | 50 | 23.66% to 76.34% | 50 | 23.66% to 76.34% |
| GR | 0.57 | 0.3009 to 0.8391 | 0.5967 | <1.719 | 50 | 23.66% to 76.34% | 50 | 23.66% to 76.34% | 0.6 | 0.3419 to 0.8581 | 0.4497 | <10.62 | 60 | 31.27% to 83.18% | 60 | 31.27% to 83.18% |
| SOD | 0.97 | 0.9071 to 1.000 | 0.0004 | <0.2066 | 90 | 59.58% to 99.49% | 90 | 59.58% to 99.49% | 1 | 1.000 to 1.000 | 0.0002 | <0.5534 | 100 | 72.25% to 100.0% | 100 | 72.25% to 100.0% |
| AA | 0.99 | 0.9583 to 1.000 | 0.0002 | <9.841 | 90 | 59.58% to 99.49% | 90 | 59.58% to 99.49% | 0.89 | 0.7500 to 1.000 | 0.0032 | <8.703 | 80 | 49.02% to 96.45% | 80 | 49.02% to 96.45% |
| GSH | 1 | 1.000 to 1.000 | 0.0002 | <0.9395 | 100 | 72.25% to 100.0% | 100 | 72.25% to 100.0% | 1 | 1.000 to 1.000 | 0.0002 | <0.4547 | 100 | 72.25% to 100.0% | 100 | 72.25% to 100.0% |
| UA | 0.9 | 0.7609 to 1.000 | 0.0025 | >0.4447 | 80 | 49.02% to 96.45% | 80 | 49.02% to 96.45% | 0.86 | 0.6739 to 1.000 | 0.0065 | >0.3867 | 80 | 49.02% to 96.45% | 80 | 49.02% to 96.45% |
| PC | 0.89 | 0.7476 to 1.000 | 0.0032 | >0.3696 | 80 | 49.02% to 96.45% | 80 | 49.02% to 96.45% | 0.95 | 0.8477 to 1.000 | 0.0007 | >0.4784 | 90 | 59.58% to 99.49% | 90 | 59.58% to 99.49% |
| 3-NT | 0.78 | 0.5536 to 1.000 | 0.0343 | >6.415 | 70 | 39.68% to 89.22% | 70 | 39.68% to 89.22% | 0.91 | 0.7557 to 1.000 | 0.0019 | >11.01 | 90 | 59.58% to 99.49% | 90 | 59.58% to 99.49% |
| AGE | 0.94 | 0.8208 to 1.000 | 0.0009 | >0.4471 | 90 | 59.58% to 99.49% | 90 | 59.58% to 99.49% | 0.95 | 0.8622 to 1.000 | 0.0007 | >1.192 | 80 | 49.02% to 96.45% | 80 | 49.02% to 96.45% |
| 4-HNE | 1 | 1.000 to 1.000 | 0.0002 | >8.293 | 100 | 72.25% to 100.0% | 100 | 72.25% to 100.0% | 1 | 1.000 to 1.000 | 0.0002 | >54.87 | 100 | 72.25% to 100.0% | 100 | 72.25% to 100.0% |
Abbreviations: 3-NT: 3-nitrotyrosine; 4-HNE: 4-hydroxynonenal; AA: ascorbic acid; AGE: advanced glycation end products; AUC: area under the curve; CAT: catalase; CI: confidence interval; GPx: glutathione peroxidase; GSH: reduced glutathione; GR: glutathione reductase; HOMA-IR: homeostatic model assessment for insulin resistance; PC: protein carbonyls; Px: peroxidase; ROC: receiver operating characteristic; SOD: superoxide dismutase; UA: uric acid.